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STEM CELLS AND REGENERATION RESEARCH ARTICLE
MAPK pathway control of stem cell proliferation and differentiation
in the embryonic pituitary provides insights into the pathogenesis
of papillary craniopharyngioma
Scott Haston1,*, Sara Pozzi1, Gabriela Carreno1, Saba Manshaei1, Leonidas Panousopoulos1,
Jose Mario Gonzalez-Meljem1, John R. Apps1, Alex Virasami2, Selvam Thavaraj3, Alice Gutteridge4,
Tim Forshew4, Richard Marais5, Sebastian Brandner6,7, Thomas S. Jacques1,2, Cynthia L. Andoniadou8,9 and
Juan Pedro Martinez-Barbera1,*
ABSTRACT
Despite the importance of the RAS-RAF-MAPK pathway in normal
physiology and disease of numerous organs, its role during pituitary
development and tumourigenesis remains largely unknown. Here, we
show that the over-activation of the MAPK pathway, through
conditional expression of the gain-of-function alleles BrafV600E
and KrasG12D in the developing mouse pituitary, results in severe
hyperplasia and abnormal morphogenesis of the gland by the end
of gestation. Cell-lineage commitment and terminal differentiation
are disrupted, leading to a significant reduction in numbers of most of
the hormone-producing cells before birth, with the exception of
corticotrophs. Of note, Sox2+ stem cells and clonogenic potential are
drastically increased in the mutant pituitaries. Finally, we reveal that
papillary craniopharyngioma (PCP), a benign human pituitary tumour
harbouring BRAF p.V600E also contains Sox2+ cells with sustained
proliferative capacity and disrupted pituitary differentiation. Together,
our data demonstrate a crucial function of the MAPK pathway in
controlling the balance between proliferation and differentiation of
Sox2+ cells and suggest that persistent proliferative capacity of Sox2+
cells may underlie the pathogenesis of PCP.
KEY WORDS: Pituitary development, Mouse, Papillary
craniopharyngioma, Sox2, Tumour
INTRODUCTION
In vertebrates, the pituitary gland is considered to be master
regulator of homeostasis because it regulates a wide range of
essential physiological functions, such as metabolism, growth,
fertility and the stress response. The pituitary gland comprises
anterior, intermediate and posterior lobes (AL, IL and PL,
respectively). The AL and IL derive from Rathke’s pouch, a
dorsal evagination of the oral ectoderm at the boundary with the
pharyngeal endoderm. The PL develops from a diverticulum at the
ventral midline of the diencephalon: the infundibulum. At 18.5 dpc,
the AL contains five hormone-expressing cell types – somatotrophs,
lactotrophs, thyrotrophs, gonadotrophs and corticotrophs – that
secrete growth hormone (GH), prolactin (PRL), thyroid-stimulating
hormone (TSH), gonadotropins (FSH and LH) and
adrenocorticotropin hormone (ACTH), respectively (Kelberman
et al., 2009). In addition, the AP contains Sox2+/Sox9+ cells, a
proportion of which represent stem cells in the postnatal pituitary
(Castinetti et al., 2011; Andoniadou et al., 2013; Rizzoti et al.,
2013). These cells are concentrated around the pituitary cleft in the
IL and the ‘marginal zone’, a region of the dorsal AL mostly devoid
of hormone-producing cells (Fauquier et al., 2008; Garcia-
Lavendeira et al., 2009; Goldsmith et al., 2016; Pérez Millán
et al., 2016). Dispersed Sox2+/Sox9+ cells are also detected
throughout the parenchyma of the AL, intermingled with
hormone-expressing cells (Mollard et al., 2012). The IL contains
melanotrophs, which express melanocyte-stimulating hormone
(MSH). The PL is devoid of endocrine cell types and contains the
axonal projections from hypothalamic neurons.
Several signalling pathways and transcription factors regulate the
normal development of the pituitary gland. Around 9.5 days post
coitum (dpc), secreted signals from the prospective hypothalamus,
such as FGF8, FGF10, BMP4 and SHH are required for RP
induction and for the expression of transcription factors, including
Hesx1, Sox2, Lhx3 and Lhx4 in RP progenitors (Ericson et al., 1998;
Treier et al., 1998, 2001). RP progenitors divide actively from 9.5 to
14.5 dpc (Davis et al., 2011) to generate post-mitotic precursors
that initiate cell-lineage commitment by expressing: (1) Sf1
(Nr5a1), in the gonadotroph cell lineage (Schimmer and White,
2010); (2) the T-box transcription factor Tpit, which is responsible
for the activation of the pro-opiomelanocortin (Pomc1) gene in
corticotrophs (and melanotrophs of the intermediate lobe) (Lamolet
et al., 2001); and (3) POU Class 1 homeobox 1 (Pou1f1 or Pit1),
which control the differentiation of thyrotrophs, lactotrophs and
somatotrophs (Dollé et al., 1990). Mouse mutants and humans
carrying inactivating mutations in most of these genes develop
hypopituitarism (Fang et al., 2016).
The mitogen-activated protein kinase (MAPK) pathway
encompasses different signalling cascades, of which the Ras-Raf-
Mek-ERK1/2 (hereafterMAPK/ERK) is one of themost dysregulatedReceived 13 February 2017; Accepted 3 May 2017
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in human cancer and, additionally, plays important roles during
normal physiology (Dhillon et al., 2007; Zhang and Liu, 2002).
Extracellular growth factors (FGFs, EGF and PDGF, among others)
bind to and activate receptor tyrosine kinases, causing a downstream
phosphorylation cascade (RAS-RAF-MEK-ERK), which eventually
leads to transcription of target genes controlling cellular proliferation,
differentiation, apoptosis and senescence. Gain-of-functionmutations
in components of the pathway, such as BRAF p.V600E and KRAS
p.G12D, have been identified in numerous tumours and cancers
(Dhillon et al., 2007). These mutations lead to the overactivation of
the MAPK/ERK pathway and increase cell proliferation and survival,
resulting in cell transformation and tumourigenesis. In pituitary
tumours, biochemical evidence indicates that this pathway is activated
in many types of pituitary adenoma in humans (Dworakowska et al.,
2009). However, mutations in components of the pathway have been
identified only in papillary craniopharyngioma (PCP); specifically,
the BRAF p.V600E mutation is present in the vast majority of the
tumours analysed (Brastianos et al., 2014).
In this manuscript, we have addressed the role of MAPK/ERK
pathway during normal pituitary development and in tumourigenesis
by conditionally activating this pathway in RP progenitors during
embryonic development. Our results demonstrate that persistent
activation of the pathway leads to a drastic increase in the proliferative
capacity of Sox2+ cells and impairment of their differentiation
properties, resulting in enlargement of the Sox2+ stem cell
compartment by the end of gestation. Additionally, expression
analysis of human tumour samples strongly suggests that similar
mechanisms underlie the pathogenesis of PCP.
RESULTS
Severe anterior lobe hyperplasia and neonatal lethality in
Hesx1Cre/+;BrafV600E/+ and Hesx1Cre/+;KrasG12D/+mutants
We have previously shown that the Hesx1-Cre mouse line drives
robust Cre-mediated activity in the developing pituitary gland by
9.0 dpc (Andoniadou et al., 2007; Gaston-Massuet et al., 2011;
Jayakody et al., 2012). To assess the role of the MAPK/ERK
pathway during development, we crossed the Hesx1Cre/+ mice with
either BrafV600E/+ or KrasG12D/+ animals (Mercer et al., 2005;
Tuveson et al., 2004). Genotypic analysis of 10.5-18.5 dpc embryos
showed no statistically significant variation from the expected
Mendelian ratios (Table S1). In contrast, genotyping of postnatal
mice from birth to 3 weeks failed to identify any viable Hesx1Cre/+;
BrafV600E/+ or Hesx1Cre/+;KrasG12D/+mice (Table S1). Histological
examination revealed the presence of expanded airway structures in
both mouse models at 18.5 dpc, suggesting that abnormal lung
development could be the cause of the perinatal death observed
(Fig. S1) (Tang et al., 2011).
Haematoxylin and Eosin staining of Hesx1Cre/+;BrafV600E/+ and
Hesx1Cre/+;KrasG12D/+ mutants at 10.5 dpc revealed no gross
morphological defects in the developing RP of these mutants
compared with control littermates (Fig. 1A-C). The first clear
evidence of a morphological defect, typically anterior pituitary
hyperplasia, was observed at 12.5 dpc and was further pronounced
by 14.5 dpc (Fig. 1D-I). At 18.5 dpc, a fully penetrant phenotype of
severe anterior pituitary hyperplasia with branched cleft was
observed in all embryos analysed (Fig. 1J-L). Cell counts of
dissociated pituitaries at 18.5 dpc revealed a total of 96,000±2.7%
in the Hesx1Cre/+;BrafV600E/+mutant (P≤0.01), 101,666±4.3% in
the Hesx1Cre/+;KrasG12D/+ mutant (P≤0.01) and 67,200±3.5% in
control wild-type mice (Fig. 1M). The posterior lobe was present
and apparently normal in Hesx1Cre/+;BrafV600E/+ and Hesx1Cre/+;
KrasG12D/+ mutant pituitaries (Fig. 1J-L). These data suggest that
RP induction occurs normally in the Hesx1Cre/+;BrafV600E/+ and
Hesx1Cre/+;KrasG12D/+ mutants, followed by an increase in
proliferation, leading to hyperplasia of the anterior pituitary by
the end of gestation.
The MAPK/ERK pathway is regulated temporally and
spatially during normal pituitary development
The expression patterns of Braf and Kras mRNA and pERK1/2
protein expression, as a readout of activated MAPK/ERK pathway,
were respectively analysed by in situ hybridisation and
immunostaining on histological sections of wild-type, Hesx1Cre/+;
BrafV600E/+ and Hesx1Cre/+;KrasG12D/+ embryos. At 10.5 dpc wild-
Fig. 1. Abnormal pituitary morphogenesis inHesx1Cre/+;KrasG12D/+ andHesx1Cre/+;BrafV600E/+mutants.Haematoxylin and Eosin staining of sagittal (A-I) or
transverse (J-L) histological sections of the developing pituitary gland in control and mutant embryos; genotypes and stages are indicated. (A-C) At 10.5 dpc,
Rathke’s pouch (RP) is morphologically comparable between genotypes. (D-I) The developing pituitary is enlarged and dysmorphic in the mutant compared with
the control pituitary at 12.5 and 14.5 dpc (arrowheads). (J-L) At 18.5 dpc, the cleft is expanded and ramified in the mutant pituitaries (arrowheads in K,L)
compared with the control (J). The posterior pituitary (PP) is comparable between genotypes. AL, anterior lobe; IL, intermediate lobe. (M) Quantification of total
numbers of cells in the control,Hesx1Cre/+;KrasG12D/+ and Hesx1Cre/+;BrafV600E/+ pituitaries at 18.5 dpc, showing a significant increase in the mutants (**P≤0.01,
Student’s t-test). Data are mean±s.e.m. Scale bars: 200 μm.
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type embryos, Braf and Kras mRNA were clearly detected in the
prospective hypothalamus, including the posterior diencephalon
and pre-optic area, in addition to the developing RP (Fig. 2A,D). At
12.5 and 14.5 dpc, transcripts were detected throughout the
developing pituitary, including the infundibulum, periluminal
epithelium and anterior lobe (Fig. 2B,E; data not shown). At
18.5 dpc, the expression domain of Kras and Braf was restricted to
the periluminal area, including the intermediate lobe and marginal
zone, with scattered cells dispersed throughout the anterior lobe
(Fig. 2C,F). The expression patterns of Braf in Hesx1Cre/+;
BrafV600E/+ (Fig. 3A-C) and Kras in Hesx1Cre/+;KrasG12D/+ (data
not shown) mutants were comparable with those in wild-type
embryos.
These expression patterns of mRNA expression did not correlate
with pERK1/2 detection at all embryonic stages. At 10.5 dpc,
pERK1/2 expression was comparable between genotypes in both
the developing hypothalamus and RP (Fig. 4A,E,I), corresponding
with Braf and Kras mRNA expression (Fig. 2). In contrast, at 12.5
and 14.5 dpc, very few pERK1/2+ cells were detected, despite the
broad expression of Braf and Kras mRNA in mutant and wild-type
embryos (Fig. 4B,C,F,G,J,K) as well as the extensive expression of
BRAF-V600E mutant protein throughout the Hesx1Cre/+;BrafV600E/+
pituitary (Fig. 3D-F). At 18.5 dpc, the expression of pERK1/2 was
noticeably increased in both Hesx1Cre/+;BrafV600E/+ and Hesx1Cre/+;
KrasG12D/+mutants compared with the control pituitaries (Fig. 4D,H,
L), and correlated with the in situ data (Figs 2 and 3; data not shown).
Together, these expression studies demonstrate that the MAPK/ERK
pathway is temporally regulated with the highest levels observed at
10.5 and 18.5 dpc. In addition, we show that most of the cells
upregulating the pathway are located in the epithelium lining the cleft,
an area enriched for Sox2+ undifferentiated embryonic precursors and
stem cells (Andoniadou et al., 2013).
Overactivation of the MAPK/ERK pathway results in
abnormal terminal differentiation of specific hormone-
producing cells
To assess the effects of the overactivation of the MAPK/ERK
pathway in Rathke’s pouch (RP) induction, cell lineage
commitment and terminal differentiation, we performed detailed
expression analyses at 10.5, 14.5 and 18.5 dpc in both mutants in
comparison with controls. The expression of Fgf10, Bmp4 and Shh
within the hypothalamus is required for Lhx3 activation in RP
progenitors (Ericson et al., 1998; Treier et al., 1998, 2001). At
10.5 dpc, the expression domains of these markers were
indistinguishable between mutants and controls, supporting the
notion that early RP induction occurs normally in the Hesx1Cre/+;
Fig. 2.Braf andKrasmRNA is detected in the developing
hypothalamus and pituitary gland. In situ hybridisation
using Braf and Kras antisense riboprobes on histological
sections of developing wild-type pituitaries. (A,D) At
10.5 dpc, weak overall expression of Braf and Kras is
detected in the prospective hypothalamus (Hyp) and
Rathke’s pouch (RP). (B,E) At 14.5 dpc, strong expression is
detected in the infundibulum (Inf ), hypothalamus (Hyp),
periluminal epithelium (PE) and developing anterior lobe
(AL). (C,F) At 18.5 dpc, expression is detected in specific
cells within the posterior pituitary (PP), intermediate lobe (IL)
and the parenchyma of the anterior lobe (AL), including the
marginal zone (MZ). Insets in C,F show the IZ and MZ at
higher magnification. Scale bars: 200 μm.
Fig. 3. Braf mRNA and BRAF-V600E protein are
expressed in the developing pituitary in Hesx1Cre/+;
BrafV600E/+ mutants. In situ hybridisation using Braf
antisense riboprobes (A-C) and immunohistochemistry
against BRAF-V600E mutant protein (D-F) on histological
sections of Hesx1Cre/+;BrafV600E/+ embryos at the indicated
stages. (A-C) Braf mRNA expression is detected in the
hypothalamic neuroepithelium (Hyp) and developing pituitary
at all stages analysed, with a similar expression pattern to the
wild-type embryos (Fig. 2A-C). (D-F) At 10.5 dpc, only a few
cells express the BRAF-V600E protein in the developing
Rathke’s pouch (RP), but numbers increased between 12.5
and 18.5 dpc. Inset in C shows the IL and MZ at higher
magnification. Scale bars: 200 μm.
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BrafV600E/+ and Hesx1Cre/+;KrasG12D/+ mutant embryos (Fig. S2).
Immunostaining against POU1F1 (PIT1), NR5A1 (SF1) and TPIT,
markers of specific cell-lineage precursors of the anterior pituitary,
revealed evident defects in the Hesx1Cre/+;BrafV600E/+ mutants
relative to control embryos at 14.5 dpc (Fig. 5A-I). Specifically, the
proportion of PIT1+ cells was significantly reduced relative to total
cells (control, 29%; Braf mutant, 4%; P=0.001), SF1+ cells were
almost absent (control, 4%; Brafmutant, 0.5%; P≤0.05) and TPIT+
Fig. 4. Temporal and spatial regulation of pERK1/2 expression developing pituitary. Immunofluorescent staining against pERK1/2 on histological sections
of control and mutant pituitaries; genotypes and stages are indicated. (A-D) Abundant pERK1/2+ cells are detected in the hypothalamus (Hyp) and Rathke’s
pouch (RP) at 10.5 dpc, but only very few cells express pERK1/2 at 12.5 and 14.5 dpc. At 18.5 dpc, most of the signal is restricted to the intermediate lobe (IL) and
marginal zone (MZ) of the anterior lobe. (E-L) A similar expression pattern is observed in bothHesx1Cre/+;KrasG12D/+ (E-H) andHesx1Cre/+;BrafV600E/+ (I-L) mutant
pituitaries. However, the pERK1/2 signal is markedly increased in 18.5 dpc pituitaries (H,L) relative to the control (D). Insets show the outlined areas at higher
magnification. Scale bars: 200 μm.
Fig. 5. Cell-lineage commitment is disrupted inHesx1Cre/+;KrasG12D/+ andHesx1Cre/+;BrafV600E/+mutants. Immunostaining (green) against the commitment
markers PIT1, SF1 and TPIT on sagittal histological sections of mutant and control embryos at 14.5 dpc. (A-I) The expression of TPIT (A,D,G) and SF1 (B,E,H) are
markedly reduced in the mutant pituitary, especially in the Hesx1Cre/+;BrafV600E/+ mutant, relative to the control. In contrast, TPIT expression is elevated in the
mutant pituitary, more apparently in the Hesx1Cre/+;BrafV600E/+ genotype (C,F,I). Blue staining is DAPI. (J) Quantification analyses demonstrate the significant
reduction of PIT1+ and SF1+ cells in both mutants relative to the control pituitary, but the increase of TPIT+ cells is significant only in the Braf mutants (*P≤0.05,
**P≤0.01, ***P≤0.001, Student’s t-test). Data are mean±s.e.m. Scale bar: 200 μm.
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cells were increased (control, 10%; Braf mutant, 26%; P=0.001)
(Fig. 5J). In the Hesx1Cre/+;KrasG12D/+ mutants, PIT1+ and SF1+
cell lineage precursors were also significantly reduced (PIT1+:
control, 29%; Kras mutant, 13%; P≤0.01; SF1+: control, 4.5%;
Kras mutant, 0.6%; P≤0.05), albeit to a lesser extent than in
Hesx1Cre/+;BrafV600E/+ mutants. Numbers of TPIT+ cells were
similar (control, 10%; Kras mutant, 12%; P=0.6156) (Fig. 5J).
Total numbers of hormone-producing cells were calculated by
adjusting the proportion of each of these cell types to the size of the
pituitary gland of the Hesx1Cre/+;BrafV600E/+, Hesx1Cre/+;KrasG12D/+
and control embryos at 18.5 dpc (see Materials and Methods). We
reasoned that this approach could avoid any bias in the quantitative
analysis due to the hyperplasia observed in the mutant pituitaries;
for example, numbers of a particular cell type could be the same in
mutant and controls but distributed in more histological sections in
the mutant pituitary, hence seeming proportionally reduced.
Overall, specific immunostaining revealed abnormal terminal
differentiation of hormone-producing cells in both Hesx1Cre/+;
BrafV600E/+ and Hesx1Cre/+;KrasG12D/+ mutants, although the effects
were more accentuated in the former (Fig. 6A-R). Specifically,
numbers of somatotrophs (GH+) (wild type, 23560; Braf mutant,
3185), lactotrophs (PRL+) (wild type, 17604; Brafmutant, 3233) and
thyrotrophs (TSH+) (wild type, 4043; Braf mutant, 664) (i.e. the Pit1
cell lineage) were significantly reduced, and gonadotrophs (FSH+)
(wild type, 6134; Brafmutant, 1686) and LH+ (wild type, 1564; Braf
mutant, 23) almost completely absent in Hesx1Cre/+;BrafV600E/+
mutant pituitaries relative to controls (Fig. 6S). Immunostaining
against αGSU (wild type, 6861; Braf mutant, 2977) confirmed the
reduction of thyrotrophs and gonadotrophs in the mutant pituitaries
(Fig. S3). In contrast, total numbers of corticotrophs (ACTH+) (wild
type, 15958; Braf mutant, 28778) appeared significantly elevated in
Hesx1Cre/+;BrafV600E/+ mutants (Fig. 6S). Abnormal differentiation
was also observed in the Hesx1Cre/+;KrasG12D/+ mutant pituitaries,
but to a lesser extent, with a reduction in numbers of thyrotrophs (wild
type, 4043; Kras mutant, 1371), gonadotrophs (FSH+) (wild type,
6134; Kras mutant, 4044) and lactotrophs (wild type, 17604; Kras
mutant, 6710). Similar to Hesx1Cre/+;BrafV600E/+ mutants, elevated
numbers of corticotrophswere also observed inHesx1Cre/+;KrasG12D/+
mutant pituitaries (wild type, 15958; Kras mutant, 21370) (Fig. 6S).
Furthermore, absolute quantification of mRNA transcripts using
quantitative RT-PCR from 18.5 dpc control, Hesx1Cre/+;
KrasG12D/+ and Hesx1Cre/+;BrafV600E/+ pituitaries revealed a
Fig. 6. Terminal differentiation of hormone-producing cells is impaired in Hesx1Cre/+;KrasG12D/+ and Hesx1Cre/+;BrafV600E/+ mutants. Immunostaining
against pituitary hormones (green) on transverse histological sections of mutant and control embryos at 18.5 dpc. (A-R) Numbers of GH+ (somatotrophs) (A-C),
PRL+ (lactotrophs) (D-F), TSH+ (thyrotrophs) (G-I), as well as FSH+ and LH+ (gonadotrophs) cells (J-O) appear reduced in the Braf and Kras mutants relative
to the control pituitary. Blue staining is DAPI. (P-R) ACTH+ cell numbers (corticotrophs and melanotrophs) look increased in the mutant pituitaries compared with
the control. (S) Quantitative analyses demonstrate a significant reduction of all of the hormone-producing cells in the Hesx1Cre/+;BrafV600E/+ mutant pituitary,
except for ACTH+ cells, which are markedly increased relative to controls. Hesx1Cre/+;KrasG12D/+mutant pituitaries show a significant decrease in the number of
only PRL+, TSH+ and FSH+ cells, and ACTH+ cell number is also increased. (T) Absolute quantitative RT-PCR analysis of Gh and Acth mRNA expression in
mutant and control pituitaries at 18.5 dpc. Significance is only reached for Gh expression, but there is a trend towards an increase in Acth expression (*P≤0.05,
**P≤0.01, ***P≤0.001, Student’s t-test). Data are mean±s.e.m. Scale bar: 200 μm.
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significant decrease in Gh and a trend towards increased Acth
mRNA in both mutant genotypes (Fig. 6T), in agreement with the
cell counts. Together, these analyses demonstrate that cell-lineage
commitment and terminal differentiation are severely disrupted
upon activation of the MAPK pathway in RP embryonic
precursors, with an overall reduction of hormone-producing cells
at the end of gestation.
Increased proliferation of the developing pituitary in
Hesx1Cre/+;BrafV600E/+ and Hesx1Cre/+;KrasG12D/+ embryos
Analysis of cell proliferation of RP progenitors was carried out at
12.5, 14.5 and 18.5 dpc in Hesx1Cre/+;BrafV600E/+, Hesx1Cre/+;
KrasG12D/+ and control pituitaries. Quantitative analysis of the
proliferation index using Ki67 staining, a marker of cycling cells,
revealed no difference at 12.5 dpc, with around 70% of total cells
being Ki67+ (Fig. 7A-C,J). However, a significant increase in Ki67+
cells at 14.5 and 18.5 dpc was observed in both mutant genotypes,
relative to stage-matched controls (Fig. 7D-J). Of note, while the
Ki67 proliferation index decreased gradually in control pituitaries
from 72% at 12.5 dpc to 22% at 18.5 dpc, this progressive
quiescence was not observed to the same degree in the Hesx1Cre/+;
KrasG12D/+ or Hesx1Cre/+;BrafV600E/+ mutants. At 18.5 dpc, the
proportion of proliferating cells fell to only 42% in Hesx1Cre/+;
KrasG12D/+ and 55% in Hesx1Cre/+;BrafV600E/+ mutant pituitaries
(Fig. 7J). Increased proliferation was also confirmed by
immunostaining against Cyclin D2, which controls G1/S cell cycle
progression and is mainly expressed in RP progenitors in the
periluminal epithelium (Bilodeau et al., 2009). Quantification of
Cyclin D2-expressing cells out of total DAPI-stained nuclei within the
periluminal epithelium revealed an increased trend in both mutant
genotypes at 12.5 dpc compared with stage-matched controls (Fig. S4).
Activation of the MAPK/ERK pathway results in expansion of
the Sox2 stem cell compartment
The restricted expression of pERK1/2 and increased proliferation of
periluminal cells, prompted us to assess whether the Sox2+ cells
could be the main population responding to the overactivation of
the MAPK/ERK pathway in our mouse models. Histological
sections of Hesx1Cre/+;BrafV600E/+, Hesx1Cre/+;KrasG12D/+ and
control pituitaries were analysed by immunostaining at different
developmental stages. At 12.5 dpc, the proportion of Sox2+ cells
was initially similar between genotypes at around 80% of total cells
(Fig. 8A-C,J). However, in control embryos, the number of Sox2+
cells fell to 21% by 18.5 dpc (P=0.0004) (Fig. 8G,J). Strikingly, in
Hesx1Cre/+;KrasG12D/+ andHesx1Cre/+;BrafV600E/+mutant pituitaries,
the high proportion of Sox2+ cells found at earlier developmental time
points was maintained, falling to only 53% (P=0.0519) and 72%
(P=0.068) of total cells at 18.5 dpc, respectively. This suggests a
trend towards a decrease in Sox2+ cell numbers although not
statistically significant (Fig. 8H-J). Further to this, levels of Sox2
mRNA were observed to be significantly increased in Hesx1Cre/+;
BrafV600E/+mutants by quantitative RT-PCR (Fig. 8K). Corroborating
the histological findings, the clonogenic potential in Hesx1Cre/+;
KrasG12D/+ and Hesx1Cre/+;BrafV600E/+ pituitaries at 18.5 dpc was
nearly three and five times higher, respectively, than in controls when
analysed in stem cell-promoting medium (Fig. 8L,M).
The described defects suggest that the MAPK pathway may
control the balance between self-renewal and differentiation of
Sox2+ progenitors during development. To further characterise
this defect, we performed a pulse-chase experiment with the
nucleotide analogue EdU, which is incorporated during the S
phase of the cell cycle. Specifically, we injected EdU at 14.5 dpc,
when most of the replicating cells are Sox2+ progenitors, and
analysed the pituitaries 48 h later at 16.5 dpc, when progenitors
have exited cell cycle to commit to specific cell lineages (Fauquier
et al., 2008; Bilodeau et al., 2009). This was performed in both
control and Hesx1Cre/+;BrafV600E/+ embryos, owing to their more
pronounced phenotype.
In control embryos, ∼25% of the initially labelled EdU cells
expressed the commitment marker PIT1 and around 21% expressed
SOX2 (Fig. 9A,C,D,F). In contrast, in Hesx1Cre/+;BrafV600E/+
mutants, the percentage of EdU+/PIT1+ cells dropped to 3% and the
proportion of EdU+/Sox2+ cells was elevated to 40% (Fig. 9B,C,E,F).
Despite the significant increase in ACTH+ cells in the mutant
pituitary at 18.5 dpc, the proportion of EdU+/TPIT+ positive in this
tracing experiment remained similar between genotypes (8% in
controls and 9% in mutants) (Fig. 9H,I). This tracking experiment
also revealed a higher proportion of EdU+/Ki67+ cells in the
Hesx1Cre/+;BrafV600E/+ mutants (25%) relative to the controls (18%)
(Fig. 9J-L). To assess which cells were labelled at 14.5 dpc, we
performed a short pulse experiment by injecting EdU in pregnant
females at 14.5 dpc and analysed the embryos 2 h later. This analysis
confirmed that the majority of the EdU+ cells expressed SOX2,
specifically 74% of labelled EdU+ cells expressed SOX2 in the
control and 87% in the Hesx1Cre/+;BrafV600E/+ mutants pituitaries,
suggesting a trend towards an increase, although not significant
(P=0.1599) (Fig. S5A-C). In the control pituitary, 6% of the EDU+
Fig. 7. Increased proliferation in theHesx1Cre/+;KrasG12D/+ andHesx1Cre/+;
BrafV600E/+mutant pituitaries. (A-I) Immunofluorescent staining against Ki67
(green) on histological sections of mutant and control embryos; genotypes and
stages are indicated. (J) Quantitative analyses of the number of Ki67+ cells out
of the total DAPI+ cells (blue) demonstrate a significant increase in the
proliferation index in the Hesx1Cre/+;KrasG12D/+ at 18.5 dpc and Hesx1Cre/+;
BrafV600E/+ at 14.5 and 18.5 dpc (*P≤0.05, **P≤0.01, ***P≤0.001, Student’s
t-test). Data are mean±s.e.m. Scale bars: 200 μm.
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cells expressed PIT1 and 1.4% expressed TPIT, while in the mutant
pituitary these proportions were 0.1% for PIT1 and 3.7% for TPIT,
both significantly different (P=0.0246, PIT1 and P=0.0490, TPIT)
(Fig. S5D-I). Three conclusions can be drawn from these EdU
studies: (1) the activation of the MAPK/ERK pathway drives
self-renewal versus differentiation of Sox2+ cells; (2) there is a
blockade in the differentiation of Sox2+ cells into PIT1 progenitors;
and (3) there is no bias in the differentiation of Sox2+ cells into the
TPIT cell lineage; rather, TPIT progenitor respond to the pathway
activation by increasing proliferation. Together, these data
demonstrate that the activation of the MAPK pathway in embryonic
precursors results in significant expansion of the Sox2+ cell
population and increased clonogenic potential. In addition, we
show that an abnormal balance between self-renewal and
differentiation contribute to these defects.
Sox2+ cells represent the major proliferating cell population
in human papillary craniopharyngioma
Higher numbers of organ-specific stem cells with reduced
differentiation potential can lead to tumourigenesis in many
organs, including the pituitary gland (Gaston-Massuet et al.,
2011). As BRAF p.V600E is the sole genetic event associated
with human papillary craniopharyngioma (PCP), we hypothesised
that overactivated MAPK in these tumours may lead to similar
cellular alterations to those observed in the Hesx1Cre/+;BrafV600E/+
mutant pituitary, i.e. expansion of the Sox2+/Sox9+ cells with
decreased differentiation capacity.
PCPs are histologically characterised by the presence of cores of
fibrovascular stroma lined by basal cells and suprabasal layers of
well-differentiated non-keratinised squamous epithelium (Fig. 10A).
PCPs are non-functional tumours, which do not express pituitary
hormones (Louis et al., 2016). In a series of archival formalin-fixed
paraffin-embedded (FFPE) PCP specimens (n=5), we confirmed the
presence of p.BRAF(V600E) mutations (Table S2) and expression
of BRAFV600E in all tumour cells (Fig. 10B). pERK1/2 staining
was more restricted and focused in areas around the fibrovascular
cores (Fig. 10E). Most of the cells in the tumours were positive
against a pan-cytokeratin antibody recognising cytokeratins, but
cells from the basal layer were negative (Fig. 10C). This was further
evidenced by immunostaining against cytokeratin 19 (Fig. 10D).
Double immunostaining revealed that the squamous epithelial tumour
components robustly expressed SOX2 and SOX9 in a gradedmanner,
with the highest expression observed in basal cells immediately in
contact with the fibrovascular cores and a progressive loss of signal
in cells away from the SOX2+/SOX9+ areas (Fig. 10F-H).
Quantification analyses demonstrated that ∼16% of these Sox2+
cells expressed Ki67 (Fig. 10I-L). Moreover, up to 91% of all cycling
cells within the tumour (excluding host-derived stroma) co-expressed
SOX2, suggesting that proliferating SOX2+ cells may be driving PCP
growth (Fig. 10L).
For comparison purposes, we assessed the proliferative potential
of Sox2+ cells during normal human embryonic pituitary
development and adulthood. At CS20 (Carnegie stage 20;
gestational day 49), an embryonic stage that is analogous to
14.5 dpc in mouse, human foetal pituitaries were predominantly
SOX2+;SOX9+, and almost the majority of these cells expressed
Ki67 (Fig. S6A-C,J-L). In contrast, adult human pituitary samples
contained very few SOX2+ cells in the anterior lobe (Fig. S6D-I),
which very rarely expressed Ki67 with an almost mutual
exclusivity between these two markers (Fig. S6M-R). These
Fig. 8. The Sox2+ stem cell compartment is increased in Hesx1Cre/+;KrasG12D/+ and Hesx1Cre/+;BrafV600E/+ mutant pituitaries. (A-I) Immunofluorescence
staining revealing the presence of SOX2+ cells (green) in the developing pituitary; genotypes and stages are indicated. The overall numbers appear elevated in
the mutant pituitary relative to the controls at all stages analysed. Blue staining is DAPI. (J) Quantitative analyses demonstrate that the number of SOX2+ cells is
significantly increased in the mutant pituitaries compared with controls at 14.5 and 18.5 dpc. (K) Absolute quantitative RT-PCR analysis of Sox2 mRNA
expression in mutant and control pituitaries at 18.5 dpc. (L,M) Culture of dissociated cells reveals a significantly higher clonogenic potential of the mutant
pituitaries relative to the controls (*P≤0.05, **P≤0.01, ***P≤0.001, Student’s t-test). Data are mean±s.e.m. Scale bars: 200 μm.
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observations suggest that, as in the mouse model, the activation of
the MAPK pathway in human PCP tumours result in increased
proliferative capacity and reduced terminal differentiation of the
SOX2+ cells.
DISCUSSION
In this article, we show that the overactivation of the MAPK
pathway in RP embryonic precursors results in increased sustained
proliferation and impaired terminal differentiation of Sox2+ cells
during development. Consequentially, by the end of gestation, the
pituitary gland contains vast numbers of Sox2+ cells, leading to an
enlargement of the pituitary stem cell compartment. Because the
Hesx1-Cre mouse line drives Cre-mediated recombination in the
anterior hypothalamus, we cannot completely rule out a
hypothalamic contribution to the observed phenotype. However,
the normal hypothalamic patterning at 10.5 dpc supports a more
relevant role for the dysregulation of the MAPK/ERK pathway in
the developing RP. Of translational relevance, we reveal the
presence of a population of Sox2+ cells in human PCP tumours
endowed with proliferating capacity but unable to differentiate into
hormone-producing pituitary cells.
Our data suggest that the activation of the MAPK/ERK pathway
by FGF ligands is crucial during pituitary development. The FGF
family of secreted factors binds to tyrosine kinase FGF receptors
Fig. 9. Abnormal balance between
self-renewal and differentiation in the
Hesx1Cre/+;BrafV600E/+ mutant
pituitaries. The nucleotide analogue
EdU was administered once to pregnant
females at 14.5 dpc and embryos were
analysed at 16.5 dpc. (A-C) Numbers of
SOX2;EdU double-positive cells are
increased in the mutant pituitary relative
to the control. (D-F) In contrast, the
proportion of PIT1;EdU double-positive
cells is dramatically reduced in the
mutant gland. (G-I) The proportion of
TPIT;EdU double-positive cells
remained constant between genotypes.
(J-L) The percentage of cycling cells
within the initially EdU-labelled
population is significantly higher in the
Hesx1Cre/+;BrafV600E/+ mutants
compared with controls (*P≤0.05,
***P≤0.001; NS, not significant;
Student’s t-test). Data are mean±s.e.m.
Scale bars: 200 μm.
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(FGFRs) to signal through the MAPK/ERK and other pathways
(Ornitz and Itoh, 2015). Several FGFs, including Fgf8, Fgf10 and
Fgf18 are expressed in the developing ventral diencephalon around
9.5-10.5 dpc (Treier et al., 1998, 2001), and loss-of-function
mutants of FGF and FGFR2 demonstrate that FGF signalling is
required for normal proliferation of RP progenitors and pituitary
morphogenesis (De Moerlooze et al., 2000; Ohuchi et al., 2000). Ex
vivo culture of RP tissue exposed to FGFs and FGF inhibitors has
revealed a crucial function for the pathway in controlling both RP
proliferation, and its downregulation is required for normal PIT1-
cell lineage specification (Ericson et al., 1998; Norlin et al., 2000).
Of note, transgenic ectopic expression of Fgf8 in the developing
pituitary using a Cga (a-GSU) promoter results in pituitary
hyperplasia and expansion of ACTH-expressing cells
(corticotrophs and melanotrophs) with a concomitant severe loss
of gonadotrophs, somatotrophs, thyrotrophs and gonadotrophs
(Treier et al., 1998), a phenotype resembling our mouse models
that activate theMAPK-ERK pathway. The data presented here raise
the possibility that other ligands such as EGF, PDGF and TGFα,
which, like FGFs, can activate the MAPK/ERK pathway, might be
important during pituitary development. Alternatively, it is also
possible that FGF is the only secreted signal activating the MAPK/
ERK pathway in RP. Further analyses are required to clarify the
contributions of other signals besides FGFs.
We reveal a crucial function of the MAPK/ERK pathway in the
control of the stem cell compartment in the pituitary by the end of
gestation. The proportion of Sox2+ cells is drastically increased and
comprises almost three-quarters of the entire cell population in the
Fig. 10. Human PCP tumours contain a population of cycling SOX2+ cells. Analysis of histological sections of human PCP tumours. (A,A′) Haematoxylin
and Eosin staining showing the presence of fibrovascular cores (black asterisks) lined by a layer of basal cells (arrowheads) and large areas of suprabasal
squamous epithelium (white asterisks). (B,B′) Immunohistochemistry revealing the expression of BRAF-V600E in a PCP tumour. Staining is present (light brown)
in the vast majority of tumour cells. Black asterisks indicate the presence of fibrovascular cores. (C,C′) Immunohistochemical detection using a pan-cytokeratin
antibody. Most of the tumour cells show positive staining (dark brown) with the exception of the basal cell layer (arrowheads) surrounding the fibrovascular cores
(black asterisks). (D,D′) Specific staining (light brown) against cytokeratin 19 showing absent staining in the basal layer cells (arrowheads) surrounding
fibrovascular cores (asterisks). The difference in the staining, from light to dark brown, is due to technical reasons (e.g. antibody used, manual or automatized
immunohistochemistry). (E,E′) Immunofluorescence staining of pERK1/2 showing expression restricted to the cells surrounding the fibrovascular cores (white
arrowheads), with some positive cells within the fibrovascular cores (white asterisk). Outlined areas in A-E are shown in A′-E′. Outlined areas in A′-E′ are shown in
the insets in A′-E′. (F-H) Double immunofluorescent staining shows the co-expression of SOX2 and SOX9 in cells surrounding the fibrovascular cores, with
stronger signal in the basal cells. (I-K) Double immunofluorescence staining reveals the co-expression of SOX2 and Ki67 in basal cells. (L) Quantification of
SOX2:Ki67 double-positive cells as a proportion of either the SOX2+ or Ki67+ populations in human PCP. Data are mean±s.e.m. of SOX2+ KI67+ and KI67+
SOX2+ cell quantifications. Scale bars: 200 μm; 100 μm in insets.
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Hesx1Cre/+;BrafV600E/+ at 18.5 dpc. Our analyses show that this
substantial expansion is due to a failure of Sox2+ embryonic
progenitors to exit the cell cycle and differentiate at earlier
developmental stages, resulting in increased clonogenic potential
by the end of gestation. In addition, pERK1/2 staining is strongly
detected in the marginal zone, a region enriched in Sox2+ stem cells
at 18.5 dpc, suggesting that the MAPK pathway has a role in
controlling stem cell specification during development and perhaps
during stem cell homeostasis postnatally.
BRAF and KRASmutations are uncommon in pituitary adenomas
(Newey et al., 2013; Reincke et al., 2015; Ronchi et al., 2016;
Välimäki et al., 2015), but the overactivation of the MAPK/ERK
pathway has been reported in these neoplasias. A mutation was
identified in codon 12 of the HRAS gene (Gly to Val) in a recurrent
prolactinoma that was highly invasive and ultimately proved to be
fatal (Karga et al., 1992). Overexpression of both BRAF mRNA
and protein has also been reported in non-functioning pituitary
adenomas (Ewing et al., 2007). Persistent MAPK/ERK pathway
activation, by expressing oncogenic KRAS-G12V, promotes
differentiation of the bi-hormonal somatolactotroph GH4
precursor cell line into a prolactin-secreting cell type but is not
sufficient to drive tumourigenesis (Booth et al., 2014). In our mouse
models, lactotroph differentiation is impaired rather than promoted,
suggesting that the cell context where the MAPK/ERK pathway is
activated (i.e. GH4 versus embryonic precursors) and/or approach
used (i.e. in vitro versus in vivo) may have a profound effect on
the phenotypic outcomes.
PCPs are benign tumours of the sellar region, mostly affecting the
elderly, and can be associated with significant morbidity when
behaving aggressively. The majority of the PCP tumours carry
BRAF p.V600E mutations, but little is known about the
consequences of the expression of this oncogenic protein
(Brastianos et al., 2014). Of interest, preliminary data indicate that
the use of inhibitors against BRAF-V600E and MEK may be of
clinical relevance (Aylwin et al., 2016; Brastianos et al., 2016). Our
mouse models have provided important insights into the molecular
pathogenesis of PCP. We reveal the presence of a population of
cycling Sox2+ cells in the basal layer surrounding the fibrovascular
cores of PCP tumours, suggesting that these cells may be driving
tumour growth. Indeed, our analysis shows that most of the cycling
cells in the tumour are contained in the Sox2+ cell compartment. It is
interesting that despite the broad expression of the BRAF-V600E
mutant protein in the tumours, pERK1/2 staining is mostly restricted
to cells surrounding the fibrovascular cores, a region enriched in
Sox2+ cells. This is very similar to our observations in the mouse
models, where the activation of the pathway, as evidenced by
pERK1/2 staining, mostly occurs in the Sox2+ cells, even if all the
pituitary cells express BRAF-V600E. In the human tumours, the
squamous epithelium, which is thought to derive from the basal cell
layer, does not express any pituitary hormone or cell-lineage
commitment marker (PIT1, TPIT and SF1, data not shown),
suggesting that, as in the mouse, the activation of the MAPK/ERK
pathway in human PCP leads to sustained proliferation and impaired
differentiation of the Sox2+ cells. Therefore, although there are
differences between human PCP and the mouse models presented
here, both have in common that Sox2+ cells represent the major
proliferative cell population and that these show impaired
differentiation potential. The perinatal lethality in Hesx1Cre/+;
BrafV600E/+ mice precluded further analysis and, therefore, we
cannot conclude whether increased numbers of mutated Sox2+ cells
in the pituitary may eventually drive the formation of PCP-like
tumours in these mice at an older age. Further refinement may be
required to model PCP more accurately [e.g. using the Sox2-
CreERT2 mouse line (Andoniadou et al., 2013)]. Although
hampered by the rarity of these tumours, further research aiming
to test whether these cycling Sox2+ cells may represent a tumour-
initiating cell population within human PCP is also warranted.
MATERIALS AND METHODS
Mice
The Hesx1Cre/+, BrafV600E/+or KrasG12D/+ mice have previously been
described (Andoniadou et al., 2007; Mercer et al., 2005; Tuveson et al.,
2004). In both the BrafV600E/+ and theKrasG12D/+mouse lines, the expression
of the oncogenic protein is activated upon Cre-mediated recombination.
Genotyping of mice and embryos was carried out by PCR on ear punch
biopsies or pieces of tissue from embryos digested in DNAreleasy (Anachem)
as per manufacturer’s instructions. The data presented in this work are
representative of examples of at least three individual embryos per genotype.
All the experiments performed in mice were carried out according to UK
Home Office guidance and approved by a local ethical committee.
Histology and in situ hybridisation on histological sections
Haematoxylin and Eosin staining was performed as previously described
(Gaston-Massuet et al., 2011). Histological processing of embryos and
in situ hybridisation on paraffin sections was performed as previously
described (Gaston-Massuet et al., 2008; Sajedi et al., 2008). The antisense
riboprobes used in this study (Fgf10, Shh, Bmp4 and Lhx3) have been
described (Gaston-Massuet et al., 2008; Sajedi et al., 2008; Jayakody et al.,
2012; Trowe et al., 2013). Full-length Braf and Kras antisense riboprobes
were obtained from Source Bioscience (PX00999A07 and
IRAVp968D072D, respectively).
EdU labelling
For EdU labelling of embryonic pituitaries, pregnant females at 14.5 dpc
were subjected to a single intra-peritoneal injection of EdU at a dose of
100 mg/kg and embryos dissected either 2 h later for short-term tracing
experiments or 48 h later at 16.5 dpc for longer term tracing. Double
immunostaining against specific markers (SOX2, PIT1, TPIT andKI67) and
EdU was conducted using the Click-It EdU imaging kit (Invitrogen)
according to manufacturer’s instructions.
Immunohistochemistry and immunofluorescence
Embryos were fixed in 4% PFA and processed for immunodetection as
previously described (Jayakody et al., 2012; Andoniadou et al., 2013).
Detection of hormones was carried out using antibodies for α-GH (NHPP
AFP-5641801), α-ACTH (10C-CR1096M1), α-TSH (NHPP AFP-
1274789), α-PRL (NHPP AFP-425-10-91), α-LH (NHPP AFP-
C697071P) and α-FSH (AFP-7798-1289) (Developmental Studies
Hybridoma Bank) at a 1:1000 dilution. Detection of pituitary lineage
commitment was performed using antibodies for α-PIT1 (a gift from
S. Rhodes, Indiana University School of Medicine, Indianapolis) and α-
TPIT (a gift from J. Drouin, Montreal Clinical Research Institute, Montreal)
at a 1:1000 dilution. α-SF1 (434200; Thermo) was used at a dilution of
1:200. Antibodies for markers of pituitary stem cells α-SOX2 (GT15098,
Immune Systems) and α-SOX9 (AB5535, Millipore) were used at a dilution
of 1:250 and 1:500, respectively. Proliferation marker antibodies α-KI67
(ab16667, Abcam) and α-Cyclin D2 (SC-593, Santa Cruz) were used at a
dilution of 1:100 and 1:200, respectively. Detection of activated MAPK
signalling cells was performed using α-pERK1/2 (9101, Cell Signaling) at a
dilution of 1:250. Cytokeratins were detected using α-pan-cytokeratin
recognising cytokeratins 5, 6, 8, 17 and 19 (DMNF116; Dako M0821) at a
dilution of 1:300, and an antibody specifically recognising cytokeratin 19
(DAKO clone RCK108; M088). Detection of oncogenic BRAF was
performed using a α-BRAF V600E antibody (Spring Bioscience; E19290)
at a dilution of 1:50.
Cell counting in vivo
All cell counting analysis were performed in three to five non-consecutive
histological sections immunostained using the relevant antibodies. PIT1,
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SF1, TPIT, KI67, SOX2 and Cyclin D2 expressing populations were
determined by taking the proportion of positive cells relative to total DAPI-
positive nuclei. Around 4000 to 7000 DAPI-positive cells and 300 to 1000
marker-positive (PIT1+, SF1+, TPIT+, KI67+, SOX2+ and Cyclin D2+)
cells were counted for each genotype. For analysis of EdU-tracing
experiments, the proportions of SOX2-, PIT1- or KI67-positive cells were
determined relative to the EdU-positive cell population. Around 500-1500
EdU-positive cells and 200-600 marker-positive cells were counted for each
genotype. Analysis of hormone-producing cell populations (GH+, PRL+,
TSH+, FSH+, LH+, ACTH+ and αGSU+) was assessed through determining
the relative proportion of hormone-positive population to total DAPI-
positive nuclei in a section. These proportions were then applied to average
cell counts of dissociated pituitaries to determine an approximation of the
absolute numbers of these populations in the pituitary. Around 5500-8500
DAPI-positive cells and 200-2500 marker-positive cells were counted for
each genotype.
Assessment of clonogenic potential
Pituitaries from Hesx1Cre/+;BrafV600E/+, Hesx1Cre/+;KrasG12D/+ and control
littermates were dissected at 18.5 dpc and the posterior lobe was removed.
Anterior pituitaries were dissociated mechanically into a single cell
suspension following incubation in an enzyme mix (0.5% w/v
collagenase type 2, Lorne Laboratories), 0.1× trypsin (Gibco) and
50 μg/ml DNaseI (Worthington) with 2.5 μg/ml Fungizone (Gibco) in
Hank’s balanced salt solution (HBSS, Gibco) for 4 h at 37°C. Cells were
then washed in HBSS, suspended in pituitary stem cell medium and seeded
at densities of 2000, 4000 and 8000 cells per well of a six-well plate for
adherent culture. Cells were cultured for 3 days at which point they were
fixed with 4% PFA and colonies were stained for Haematoxylin, as
previously described (Gaston-Massuet et al., 2011). The proportion of
colonies observed after 3 days of culture relative to seeded cells was used to
estimate total clonogenic cells in 18.5 dpc pituitaries by multiplying this
value by the total number of cells quantified following dissociation of the
pituitary.
RNA extraction and quantitative real-time PCR
Pituitaries from Hesx1Cre/+;BrafV600E/+ or Hesx1Cre/+;KrasG12D/+ and
control littermates were dissected at 18.5 dpc. The posterior lobe of the
pituitary was discarded, and the intermediate and anterior lobes were
processed for total RNA extraction using the RNeasy Micro kit (Qiagen).
Approximately 1 μg of total RNA was reverse transcribed to cDNA using
the iScript Reverse Transcription Kit and random hexamers (Bio-Rad).
Quantitative real-time PCR reactions were run in triplicate using the iTaq
SYBR Green (Bio-Rad) and repeated for a minimum of three independent
samples for each genotype. Primer sequences are available on request. The
absolute number of mRNA copies was determined for each sample by
comparison of obtained Cq values with that of a standard of known copy
number for each transcript investigated. Variations in input cDNA used for
each reaction were accounted for by normalising differences in Gapdh
expression between samples and genotypes, and applying this normalisation
factor to absolute copy numbers obtained for each mRNA species of
interest. Primer sequences can be found in Table S3.
Human pituitaries and papillary craniopharyngioma samples
Anonymised archival frozen and FFPE specimens of PCP were accessed
through Brain UK (University of Southampton, UK). Human foetal
pituitary tissue was accessed through the Human Developmental Biology
Resource (HDBR, Newcastle and London, UK). Anonymised post-mortem
human adult pituitary was accessed from the Medical Research Council
Edinburgh Brain and Tissue bank and Royal Victoria Infirmary (Newcastle,
UK) (Ethical approval 14/LO/2265).
Detection of BRAF p.V600E mutations in papillary
craniopharyngioma tumours
DNAwas diluted fivefold with nuclease-free water (Ambion). Each digital
PCR reaction was made up to 20 µl with 2 µl diluted DNA, 10 µl ddPCR
Supermix for Probes (No dUTP; Bio-Rad), forward and reverse primers,
dual-labelled probes for wild-type and mutant templates, and nuclease-free
water. Sequences for the BRAF-V600E assay oligonucleotides are from
Hindson et al. (2011), and were used at the concentrations stated. Reactions
were partitioned into ∼23,000 droplets with Droplet Generation Oil for
Probes (Bio-Rad) using the QX200 Droplet Generator (Bio-Rad). All
samples were tested in duplicate, with no-template controls included in
all columns. Standard cycling conditions, as recommended by the
manufacturer were used with a Ta of 60°C. Results were analysed with
QuantaSoft software, v1.7. A mean of 19,080 droplets were successfully
read in each well, including controls. Two droplets positive for wild-type
template were seen in the negative controls, indicating a negligible degree of
contamination.
Statistics
Mendelian ratios were evaluated using the chi-squared test. Clonogenic
potential of control, Hesx1Cre/+;KrasG12D/+ and Hesx1Cre/+;BrafV600E/+
pituitaries was evaluated using a paired t-test. Total cell counts of control
and mutant pituitaries and quantitative real-time PCR data were analysed by
unpaired t-test.
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PérezMillán, M. I., Brinkmeier, M. L., Mortensen, A. H. andCamper, S. A. (2016).
PROP-1 triggers epithelial-mesenchymal transition-like proces in pituitary stem
cells. Elife 5, e14470.
Reincke, M., Sbiera, S., Hayakawa, A., Theodoropoulou, M., Osswald, A.,
Beuschlein, F., Meitinger, T., Mizuno-Yamasaki, E., Kawaguchi, K., Saeki, Y.
et al. (2015). Mutations in the deubiquitinase gene USP8 cause Cushing’s
disease. Nat. Genet. 47, 31-38.
Rizzoti, K., Akiyama, H. and Lovell-Badge, R. (2013). Mobilized adult pituitary
stem cells contribute to endocrine regeneration in response to physiological
demand. Cell Stem Cell 13, 419-432.
Ronchi, C. L., Peverelli, E., Herterich, S., Weigand, I., Mantovani, G.,
Schwarzmayr, T., Sbiera, S., Allolio, B., Honegger, J., Appenzeller, S. et al.
(2016). Landscape of somatic mutations in sporadic GH-secreting pituitary
adenomas. Eur. J. Endocrinol. 174, 363-372.
Sajedi, E., Gaston-Massuet, C., Signore, M., Andoniadou, C. L., Kelberman, D.,
Castro, S., Etchevers, H. C., Gerrelli, D., Dattani, M. T. and Martinez-Barbera,
J. P. (2008). Analysis of mousemodels carrying the I26T and R160C substitutions
in the transcriptional repressor HESX1 as models for septo-optic dysplasia and
hypopituitarism. Dis. Model. Mech. 1, 241-254.
Schimmer, B. P. and White, P. C. (2010). Minireview: steroidogenic factor 1: its
roles in differentiation, development, and disease. Mol. Endocrinol. 24,
1322-1337.
Tang, N., Marshall, W. F., McMahon, M., Metzger, R. J. and Martin, G. R. (2011).
Control of mitotic spindle angle by the RAS-regulated ERK1/2 pathway
determines lung tube shape. Science 333, 342-345.
Treier, M., Gleiberman, A. S., O’Connell, S. M., Szeto, D. P., McMahon, J. A.,
McMahon, A. P. and Rosenfeld, M. G. (1998). Multistep signaling requirements
for pituitary organogenesis in vivo. Genes Dev. 12, 1691-1704.
Treier, M., O’Connell, S., Gleiberman, A., Price, J., Szeto, D. P., Burgess, R.,
Chuang, P. T., McMahon, A. P. and Rosenfeld, M. G. (2001). Hedgehog
signaling is required for pituitary gland development. Development 128, 377-386.
Trowe, M.-O., Zhao, L., Weiss, A.-C., Christoffels, V., Epstein, D. J. and Kispert,
A. (2013). Inhibition of Sox2-dependent activation of Shh in the ventral
diencephalon by Tbx3 is required for formation of the neurohypophysis.
Development 140, 2299-2309.
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S.,
Mercer, K. L., Grochow, R., Hock, H., Crowley, D. et al. (2004). Endogenous
oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and
developmental defects. Cancer Cell 5, 375-387.
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